New cancer drug to begin trials in multiple myeloma patients

Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year at the Imperial CRF.

In a paper published today in the journal Cancer Cell, the researchers report how the drug, known as DTP3, kills myeloma cells in laboratory tests in human cells and mice, without causing any toxic side effects, which is the main problem with most other cancer drugs. The new drug works by stopping a key process that allows cancer cells to multiply.

Read more about the research here.

New cancer drug to begin trials in multiple myeloma patients